

POLICY NAME	Apomorphine Hydrochloride (apomorphine HCL)	POLICY #	1072P
--------------------	---------------------------------------------	-----------------	--------------

Criteria

Treatment of Parkinson's Disease

- ☐ Current treatment with at least one anti-Parkinson's agent
- ☐ Hypomobility "off" episodes or unpredictable on/off episodes
- ☐ Documented failure of levodopa dose modification such as shortening of dosing interval
- ☐ Documented failure, intolerance, or contraindication to a dopamine agonist such as pramipexole, ropinirole
- ☐ Documented failure, intolerance, or contraindication to the use of a catechol-O-methyltransferase inhibitor such as entacapone or tolcapone
- ☐ Documented failure, intolerance, or contraindication to the use of a monoamine oxidase-B inhibitor such as rasagiline or selegiline
- ☐ Documentation indicating Apokyn will NOT be used concomitantly with a 5HT3 antagonist such as ondansetron